EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate

EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate

A recent study showed that the drug ONP-002, administered through a nasal spray device, effectively targets areas in the nose connected to the brain, enhancing its potential to treat concussions.

Read More

Did you find this insightful?